Effects of a Hydrolyzed Lignin Derivative on Bleomycin-Induced Pulmonary Fibrosis in Mice.

IF 0.9 4区医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL

Bulletin of Experimental Biology and Medicine Pub Date : 2024-07-02 DOI:10.47056/0365-9615-2024-177-1-47-52

E. A. Gubareva, A. G. Golubev, A. L. Semenov, M. Yurova, S. S. Kruglov, E. A. Radetskaya

引用次数: 0

Abstract

Female C57BL/J mice with pulmonary fibrosis induced by injections of bleomycin (20 mg/kg intraperitoneally, 8 times for 4 weeks) were treated with a lignin derivative-based composition BP-C3 (80 mg/kg, daily intragastric administrations for 4 weeks). Bleomycin treatment increased the severity of pulmonary fibrosis (Ashcroft score increased from 1.43±0.20 to 4.17±0.48) and the percentage of α-SMA+ tissue (from 15.22±1.01 to 33.12±2.30%) and DNA-synthetizing nuclei (from 1.05±0.14 to 3.38±0.375). After treatment with BP-C3, we observed a tendency to a decrease in Ashcroft score (to 3.40±0.51) and a significant decrease in the percentage of α-SMA+ tissue to 24.30±1.70%; the percentage of DNA-synthetizing nuclei decreased to a lesser extent (to 3.03±0.22%). These results suggest that BP-C3 has a moderate antifibrotic activity.

查看原文本刊更多论文

水解木质素衍生物对博莱霉素诱导的小鼠肺纤维化的影响

雌性 C57BL/J 小鼠腹腔注射博莱霉素（20 毫克/千克，8 次，4 周）诱发肺纤维化，用木质素衍生物成分 BP-C3 治疗（80 毫克/千克，每天胃内给药，4 周）。博莱霉素治疗增加了肺纤维化的严重程度（Ashcroft评分从1.43±0.20增加到4.17±0.48）、α-SMA+组织的百分比（从15.22±1.01增加到33.12±2.30%）和DNA合成核的百分比（从1.05±0.14增加到3.38±0.375）。使用 BP-C3 治疗后，我们观察到 Ashcroft 评分有下降趋势（下降至 3.40±0.51），α-SMA+ 组织的百分比显著下降至 24.30±1.70%；DNA 合成核的百分比下降幅度较小（下降至 3.03±0.22%）。这些结果表明，BP-C3 具有适度的抗纤维化活性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bulletin of Experimental Biology and Medicine 医学-医学：研究与实验

CiteScore

1.50

自引率

14.30%

发文量

265

审稿时长

2 months

期刊介绍： Bulletin of Experimental Biology and Medicine presents original peer reviewed research papers and brief reports on priority new research results in physiology, biochemistry, biophysics, pharmacology, immunology, microbiology, genetics, oncology, etc. Novel trends in science are covered in new sections of the journal - Biogerontology and Human Ecology - that first appeared in 2005. World scientific interest in stem cells prompted inclusion into Bulletin of Experimental Biology and Medicine a quarterly scientific journal Cell Technologies in Biology and Medicine (a new Russian Academy of Medical Sciences publication since 2005). It publishes only original papers from the leading research institutions on molecular biology of stem and progenitor cells, stem cell as the basis of gene therapy, molecular language of cell-to-cell communication, cytokines, chemokines, growth and other factors, pilot projects on clinical use of stem and progenitor cells. The Russian Volume Year is published in English from April.